New York, USA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight The dynamics of the non-melanoma skin cancer market are anticipated to change in the coming years due to the improvement in the rise in healthcare spending across the world. Key players, such as Sirnaomics, AiViva BioPharma, Replimune, and others, are developing drugs for NMSC.
DelveInsight’s Non-melanoma Skin Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging non-melanoma skin cancer drugs, market share of individual therapies, and current and forecasted non-melanoma skin cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Non-melanoma Skin Cancer Market Report According to DelveInsight’s analysis, the market size of non-melanoma skin cancer in the 7MM is expected to grow at a significant CAGR by 2034. As per DelveInsight’s estimate, men with melanoma generally have lower survival rates than women with melanoma.
In the United States, around 3.6 million cases of BCC and 1.8 million cases of SCC are diagnosed annually, with the incidence increasing with age.
Prominent companies working in the domain of non-melanoma skin cancer, including Sirnaomics, AiViva Biopharma, Replimune, DermBiont, Inc., TuHURA Biosciences, Inc., Sano.
